12/3
04:32 pm
mrsn
Mersana Therapeutics (NASDAQ:MRSN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/30
05:30 am
mrsn
How Mersana's Acquisition Is Changing the Story and Analyst Outlook for Investors [Yahoo! Finance]
Low
Report
How Mersana's Acquisition Is Changing the Story and Analyst Outlook for Investors [Yahoo! Finance]
11/16
07:04 pm
mrsn
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN
Low
Report
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN
11/15
07:05 pm
mrsn
How the Acquisition Is Reshaping Mersana Therapeutics' Story and Analyst Outlook [Yahoo! Finance]
Low
Report
How the Acquisition Is Reshaping Mersana Therapeutics' Story and Analyst Outlook [Yahoo! Finance]
11/15
10:33 am
mrsn
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
11/15
10:33 am
mrsn
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating.
11/14
09:42 am
mrsn
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at Guggenheim.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at Guggenheim.
11/14
08:10 am
mrsn
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results [Yahoo! Finance]
11/14
07:52 am
mrsn
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Wedbush from a "strong-buy" rating to a "hold" rating.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Wedbush from a "strong-buy" rating to a "hold" rating.
11/14
07:46 am
mrsn
Halper Sadeh LLC Encourages MRSN, THS, HBAN Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages MRSN, THS, HBAN Shareholders to Contact the Firm to Discuss Their Rights
11/14
07:00 am
mrsn
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results
Low
Report
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results
11/13
06:12 pm
mrsn
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at William Blair to a "market perform" rating.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at William Blair to a "market perform" rating.
11/13
02:57 pm
mrsn
Day One Biopharmaceuticals: Mersana Acquisition Ignites March Towards Unmet Need [Seeking Alpha]
Low
Report
Day One Biopharmaceuticals: Mersana Acquisition Ignites March Towards Unmet Need [Seeking Alpha]
11/13
01:39 pm
mrsn
Mersana Therapeutics (NASDAQ:MRSN) had its "hold" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $30.75 price target on the stock, down previously from $36.00.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) had its "hold" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $30.75 price target on the stock, down previously from $36.00.
11/13
12:56 pm
mrsn
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at BTIG Research.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at BTIG Research.
11/13
11:35 am
mrsn
Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Low
Report
Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
11/13
08:12 am
mrsn
MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders
Low
Report
MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders
11/13
06:30 am
mrsn
Day One to buy Mersana Therapeutics for $25/share upfront [Seeking Alpha]
Low
Report
Day One to buy Mersana Therapeutics for $25/share upfront [Seeking Alpha]
11/13
06:00 am
mrsn
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
High
Report
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
11/10
08:18 am
mrsn
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025 [Yahoo! Finance]
Low
Report
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025 [Yahoo! Finance]
11/10
08:00 am
mrsn
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
Low
Report
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
10/25
12:09 pm
mrsn
Mersana Therapeutics (NASDAQ:MRSN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Mersana Therapeutics (NASDAQ:MRSN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/14
09:20 pm
mrsn
Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum's Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications [Yahoo! Finance]
Low
Report
Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum's Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications [Yahoo! Finance]
9/8
06:23 pm
mrsn
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High? [Yahoo! Finance]
Medium
Report
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High? [Yahoo! Finance]